Prevalence and determinants of anticholinergic medication use in elderly dementia patients

Drugs and Aging

Volumn 30, Issue 10, 2013, Pages 837-844

  Sura, Sneha D ^a   Carnahan, Ryan M ^b   Chen, Hua ^a   Aparasu, Rajender R ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ATROPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CYCLOBENZAPRINE; CYPROHEPTADINE; DARIFENACIN; HYDROXYZINE; MECLOZINE; MEMANTINE; OXYBUTYNIN; RANITIDINE; TOLTERODINE;

AGED; ANTICHOLINERGIC EFFECT; ARTICLE; BIPOLAR MANIA; CONCEPTUAL FRAMEWORK; CROSS-SECTIONAL STUDY; DAILY LIFE ACTIVITY; DEMENTIA; DEPRESSION; DRUG USE; EDUCATIONAL STATUS; ELDERLY CARE; FEMALE; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEALTH SERVICE; HEALTH STATUS; HIGH RISK PATIENT; HUMAN; ICD-9-CM; INCOME; MALE; MARRIAGE; MENTAL HEALTH; MOOD DISORDER; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; RACE; RETROSPECTIVE STUDY; URINE INCONTINENCE;

AGED; AGED, 80 AND OVER; CHOLINERGIC ANTAGONISTS; DATA COLLECTION; DEMENTIA; FEMALE; HUMANS; MALE;

EID: 84890198870     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-013-0104-x     Document Type: Article

References (50)

1. Simonson W, Feinberg JL. Medication-related problems in the elderly: defining the issues and identifying solutions. Drugs Aging. 2005;22(7):559-69. (Pubitemid 41214549)
2. Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007;5(4):345-51.
3. Zhang M, Holman CD, Price SD, Sanfilippo FM, Preen DB, Bulsara MK. Comorbidity and repeat admission to hospital for adverse drug reactions in older adults: retrospective cohort study. BMJ. 2009;338:a2752.
4. Hanlon JT, Fillenbaum GG, Schmader KE, Kuchibhatla M, Horner RD. Inappropriate drug use among community-dwelling elderly. Pharmacotherapy. 2000;20(5):575-82. (Pubitemid 30252984)
5. Curtis LH, Ostbye T, Sendersky V, Hutchison S, Dans PE, Wright A, et al. Inappropriate prescribing for elderly Americans in a large outpatient population. Arch Intern Med. 2004;164(15):1621-5. (Pubitemid 39037940)
6. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163(22):2716-24. (Pubitemid 37517412)
7. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60(4):616-31.
8. Fibiger HC, Damsma G, Day JC. Behavioral pharmacology and biochemistry of central cholinergic neurotransmission. Adv Exp Med Biol. 1991;295:399-414.
9. Peters NL. Snipping the thread of life. Antimuscarinic side effects of medications in the elderly. Arch Intern Med. 1989;149(11):2414-20. (Pubitemid 19283196)
10. Feinberg M. The problems of anticholinergic adverse effects in older patients. Drugs Aging. 1993;3(4):335-48.
11. Lieberman JA 3rd. Managing anticholinergic side effects. Prim Care Companion J Clin Psychiatry. 2004;6(Suppl 2):20-3.
12. Rochon PA, Gurwitz JH. Drug therapy. Lancet. 1995;346(8966):32-6.
13. Flaherty JH. Psychotherapeutic agents in older adults. Commonly prescribed and over-the-counter remedies: causes of confusion. Clin Geriatr Med. 1998;14(1):101-27. (Pubitemid 28140878)
14. Gray SL, Lai KV, Larson EB. Drug-induced cognition disorders in the elderly: incidence, prevention and management. Drug Saf. 1999;21(2):101-22. (Pubitemid 29389171)
15. Moore AR, O'Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs Aging. 1999;15(1):15-28. (Pubitemid 29358484)
16. Schliebs R, Arendt T. The cholinergic system in aging and neuronal degeneration. Behav Brain Res. 2011;221(2):555-63.
17. Sunderland T, Tariot P, Murphy DL, Weingartner H, Mueller EA, Cohen RM. Scopolamine challenges in Alzheimer's disease. Psychopharmacology (Berl). 1985;87(2):247-9. (Pubitemid 16253356)
18. Sunderland T, Tariot PN, Cohen RM, Weingartner H, Mueller EA 3rd, Murphy DL. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study. Arch Gen Psychiatry. 1987;44(5):418-26. (Pubitemid 17064486)
19. Roe CM, Anderson MJ, Spivack B. Use of anticholinergic medications by older adults with dementia. J Am Geriatr Soc. 2002;50(5):836-42. (Pubitemid 34496679)
20. Carnahan RM, Lund BC, Perry PJ, Chrischilles EA. The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice? J Am Geriatr Soc. 2004;52(12):2082-7. (Pubitemid 41725028)
21. Chatterjee S, Mehta S, Sherer JT, Aparasu RR. Prevalence and predictors of anticholinergic medication use in elderly nursing home residents with dementia: analysis of data from the 2004 National Nursing Home Survey. Drugs Aging. 2010;27(12):987-97.
22. Bhattacharya R, Chatterjee S, Carnahan RM, Aparasu RR. Prevalence and predictors of anticholinergic agents in elderly outpatients with dementia. Am J Geriatr Pharmacother. 2011;9(6):434-41.
23. Cohen JW, Cohen SB, Banthin JS. The medical expenditure panel survey: a national information resource to support healthcare cost research and inform policy and practice. Med Care. 2009;47(7 Suppl 1):S44-50.
24. Medical Expenditure Panel Survey. Agency for Healthcare Research and Quality (AHRQ) (Online). http://meps.ahrq.gov/mepsweb/index.jsp. Accessed 25 Aug 2012.
25. Kamble P, Chen H, Sherer JT, Aparasu RR. Use of antipsychotics among elderly nursing home residents with dementia in the US: an analysis of National Survey Data. Drugs Aging. 2009;26(6):483-92.
26. Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR. The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006;46(12):1481-6. (Pubitemid 44704208)
27. Modi A, Weiner M, Craig BA, Sands LP, Rosenman MB, Thomas J 3rd. Concomitant use of anticholinergics with acetylcholinesterase inhibitors in Medicaid recipients with dementia and residing in nursing homes. J Am Geriatr Soc. 2009;57(7):1238-44.
28. Andersen R, Newman JF. Societal and individual determinants of medical care utilization in the United States. Milbank Mem Fund Q Health Soc. 1973;51(1):95-124.
29. Andersen RM. Revisiting the behavioral model and access to medical care: does it matter? J Health Soc Behav. 1995;36(1):1-10.
30. Rosen RC, Zozula R, Jahn EG, Carson JL. Low rates of recognition of sleep disorders in primary care: comparison of a community-based versus clinical academic setting. Sleep Med. 2001;2(1):47-55. (Pubitemid 32184401)
31. Kemper RF, Steiner V, Hicks B, Pierce L, Iwuagwu C. Anticholinergic medications: use among older adults with memory problems. J Gerontol Nurs. 2007;33(1):21-9 (quiz 30-1).
32. Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168(5):508-13. (Pubitemid 351547214)
33. Edwards KR, O'Connor JT. Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors. J Am Geriatr Soc. 2002;50(6):1165-6. (Pubitemid 34666332)
34. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. Arch Intern Med. 1997;157(14):1531-6. (Pubitemid 27305197)
35. Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC. Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. Arch Intern Med. 1991;151(9):1825-32.
36. Jano E, Aparasu RR. Healthcare outcomes associated with Beers' criteria: a systematic review. Ann Pharmacother. 2007;41(3):438-47. (Pubitemid 46536035)
37. Lau DT, Kasper JD, Potter DE, Lyles A. Potentially inappropriate medication prescriptions among elderly nursing home residents: their scope and associated resident and facility characteristics. Health Serv Res. 2004;39(5):1257-76. (Pubitemid 39318923)
38. Shrank WH, Polinski JM, Avorn J. Quality indicators for medication use in vulnerable elders. J Am Geriatr Soc. 2007;55(Suppl 2):S373-82. (Pubitemid 47515348)
39. Zhang Y, Baicker K, Newhouse JP. Geographic variation in the quality of prescribing. N Engl J Med. 2010;363(21):1985-8.
40. Qato DM, Trivedi AN. Receipt of high risk medications among elderly enrollees in Medicare Advantage plans. J Gen Intern Med. 2013;28(4):546-53.
41. Meyers BS. Depression and dementia: comorbidities, identification, and treatment. J Geriatr Psychiatry Neurol. 1998;11(4):201-5. (Pubitemid 29178747)
42. Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D'Angelo K. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc. 1998;46(1):8-13. (Pubitemid 28037667)
43. Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function of the elderly population: effects of darifenacin. J Urol. 2005;173(2):493-8.
44. Kay GG, Ebinger U. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract. 2008;62(11):1792-800.
45. Specht JK. Promoting continence in individuals with dementia. J Gerontol Nurs. 2011;37(2):17-21.
46. Hagglund D. A systematic literature review of incontinence care for persons with dementia: the research evidence. J Clin Nurs. 2010;19(3-4):303-12.
47. Gill SS, Mamdani M, Naglie G, Streiner DL, Bronskill SE, Kopp A, et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med. 2005;165(7):808-13. (Pubitemid 40569436)
48. Antivert (package insert). New York: Pfizer, Inc; 2006.
49. Forrester CM, Benfield DA Jr, Matern CE, Kelly JA, Pellegrini JE. Meclizine in combination with ondansetron for prevention of postoperative nausea and vomiting in a high-risk population. AANA J. 2007;75(1):27-33. (Pubitemid 46214150)
50. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006(1):CD005593.